Business Context and Reporting Period
Company: Novartis AG
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Reporting Currency: US Dollars (changed from Swiss Francs effective January 1, 2003)
Business Overview: Novartis is a global healthcare company organized into two primary divisions: Pharmaceuticals (64% of sales) and Consumer Health (36% of sales). The Consumer Health division includes Sandoz (generics), OTC, Animal Health, Medical Nutrition, Infant & Baby, and CIBA Vision.
Key Financial Metrics (2003)
| Metric | 2003 (IFRS) | 2002 (IFRS) | Change |
|---|---|---|---|
| Net Sales | $24,864 million | $20,877 million | +19% |
| Operating Income | $5,889 million | $5,092 million | +16% |
| Net Income | $5,016 million | $4,725 million | +6% |
| Operating Margin | 23.7% | 24.4% | -0.7 pp |
| Net Income Margin | 20.2% | 22.6% | -2.4 pp |
| Cash Flow from Operations | $6,652 million | $5,229 million | +27% |
| Free Cash Flow | $3,628 million | $2,958 million | +23% |
| Total Assets | $49,317 million | $45,025 million | N/A |
| Total Equity | $30,429 million | $28,269 million | N/A |
| Net Liquidity | $7,289 million | $6,972 million | N/A |
| Financial Debt | $6,000 million | $5,600 million | N/A |
Note: US GAAP Net Income for 2003 was $3,788 million due to differences in accounting for goodwill, share-based compensation, and in-process R&D.
Material Changes vs. Prior Period
- Sales Growth Drivers: Sales increased 19% in US dollars (11% in local currencies). Growth was driven by an 8% volume increase, a 1% price increase, and a 2% acquisition contribution. A significant 8% positive currency effect resulted from the weakening US dollar against the Swiss franc, Euro, and Yen.
- Division Performance:
- Pharmaceuticals: Sales rose 18% (11% local currency), driven by cardiovascular (Diovan, Lotrel) and oncology (Gleevec, Zometa) franchises.
- Sandoz (Generics): Sales surged 60% (47% local currency) due to the integration of Lek Pharmaceuticals and strong US sales of generic AmoxC and Loratadine.
- Consumer Health: Ongoing business sales grew 24% (16% local currency).
- Expense Trends:
- R&D: Increased 32% to $3.8 billion (15.1% of sales) due to milestone payments on in-licensed compounds and the expansion of the Cambridge research facility.
- Marketing & Sales: Increased 17% to $7.9 billion, though as a percentage of sales, it decreased by 0.7 percentage points.
- General & Administration: Increased 21% due to asset write-downs ($136 million) and biotech investment write-downs ($80 million), partially offset by the release of legal provisions ($90 million) following a settlement with GlaxoSmithKline.
- Associated Companies: Results from associated companies turned negative ($200 million loss) compared to a small loss in 2002. This was primarily due to Novartis' share of Roche Holding AG's unexpected 2002 loss booked in 2003 ($269 million) and goodwill amortization.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects to maintain capital expenditure at approximately 5.2% of sales in 2004, funded by internally generated resources. The company anticipates continued pressure on pricing and operating results due to government initiatives to reduce patient reimbursement and increase generic usage.
Key Risks
- Patent Expirations: Significant revenue risks exist for products like Neoral, Sandostatin, Lotrel, Lamisil, and Miacalcin as patents expire or face generic challenges. Specifically, the basic benazepril patent for Lotrel/Cibacen expires in the US in February 2004.
- Regulatory & Pricing: Intense price controls in Europe and Japan, and potential Medicare reform impacts in the US. Cross-border sales (parallel trade) in the EU pose additional pricing risks.
- Product Liability & Litigation: Ongoing litigation regarding PPA (phenylpropanolamine), Average Wholesale Price (AWP) allegations, and antitrust claims. A US Department of Justice investigation is ongoing regarding marketing practices in the US enteral pump market.
- Environmental: Potential liabilities for remediation of contaminated sites, though management believes current reserves are adequate.
Unusual Items
- Acquisitions: Acquired 51% of Idenix Pharmaceuticals ($255 million initial payment) and rights to Enablex from Pfizer (up to $225 million). Announced agreement to acquire Mead Johnson's adult medical nutrition business for $385 million (pending regulatory review).
- Divestitures: Divested Food & Beverage business in late 2002; results are now excluded from ongoing operations.
- Share Repurchases: Repurchased 24.3 million shares for $939 million in 2003. Proposed a new CHF 3 billion repurchase program.
Important Facts for Investor Verification
- Patent Cliff Timeline: Verify the specific expiration dates and generic entry status for key revenue drivers: Neoral, Sandostatin, Lotrel, Lamisil, and Miacalcin.
- Roche Investment Impact: Confirm the valuation and future earnings contribution of the ~33% stake in Roche Holding AG, which significantly impacted 2003 net income.
- US GAAP vs. IFRS Reconciliation: Review the significant differences in Net Income ($5.0B IFRS vs. $3.8B US GAAP) driven by goodwill amortization, share-based compensation, and in-process R&D write-offs.
- Legal Proceedings: Monitor the status of the US DOJ investigation into the enteral pump market and the PPA product liability lawsuits.
- Dividend Policy: Verify the proposed dividend of CHF 1.00 per share for 2003, noting the impact of exchange rate fluctuations on USD-denominated dividends.